Ismidenon (AD101)
Alzheimer's Disease
Phase 2/3Active
Key Facts
About AmyriAD Therapeutics
AmyriAD Therapeutics is a private, pre-revenue biotech founded in 2020, advancing Ismidenon (formerly AD101), a once-daily oral small molecule for Alzheimer's disease. The company is preparing for a Phase 2/3 registration trial in the US, targeting the enhancement of cholinergic tone in patients already on standard therapy like donepezil. Its leadership team boasts a legacy of success in Alzheimer's drug development, positioning the company to address a core symptomatic pathway with a potentially improved safety profile. The firm operates in the high-need, high-value Alzheimer's therapeutics market.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |